Business Wire
21 Sept 2026, 06:00 UTC · 2h ago
Verdict
Headline takes no side. We score TEVA +0.40 across two claims — moderately bullish.
+0.40moderately bullish
More positive than 58% of ticker scores this week
What the story claims
2 claims · scored −1 bearish … +1 bullish · 2 new · 0 priced in
Teva presented new post hoc analyses from the Phase 3 SOLARIS trial for its investigational once-monthly subcutaneous olanzapine LAI.
Newpresented at Psych Congress 2026, held September 15 to 19
So whatPositive Phase 3 post hoc data typically streamlines the final NDA submission process, potentially accelerating a 2027 launch.
More positive than 76% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
New data was presented regarding UZEDY®, a treatment utilizing Medincell's licensed SteadyTeq™ technology.
Newpresented at Psych Congress 2026, held September 15 to 19
So whatEvidence of improved real-world utility for UZEDY could increase royalty streams for Medincell in the coming fiscal year.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 58% of ticker scores this week
Teva presented new positive post hoc analyses from a Phase 3 trial for its investigational olanzapine LAI.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
2h ago
—
TEVA hasn't traded since this ran. Last close $38.98 (Sep 18); the reaction starts at the next open.
TEVA chart →
